Log in

PSRX Psyrex CNS Bio-Tech Ltd. TASE · Israel

Psyrex CNS Bio-Tech (PSRX) news

Psyrex CNS Bio-Tech Ltd. is a public biotech or pharmaceutical company listed on TASE under the ticker PSRX, recorded under Israel. The directory classifies it as Mixed biopharma / other operations. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Latest Psyrex CNS Bio-Tech news

We have not published a story on Psyrex CNS Bio-Tech yet. When there is news, it will appear here.

Questions about Psyrex CNS Bio-Tech

What is the ticker symbol of Psyrex CNS Bio-Tech?

Psyrex CNS Bio-Tech Ltd. trades under the ticker PSRX on TASE.

Where is Psyrex CNS Bio-Tech listed?

Psyrex CNS Bio-Tech Ltd. is listed on TASE.

Which country or territory is Psyrex CNS Bio-Tech listed under?

Our directory records Psyrex CNS Bio-Tech Ltd. under Israel.

What does Psyrex CNS Bio-Tech do?

Our directory classifies Psyrex CNS Bio-Tech Ltd. as: Mixed biopharma / other operations. This is a directory classification, not a description of the pipeline.

What is the ISIN of Psyrex CNS Bio-Tech?

The ISIN recorded for Psyrex CNS Bio-Tech Ltd. is IL0011769085.

Does aibio.space cover Psyrex CNS Bio-Tech?

aibio.space lists Psyrex CNS Bio-Tech Ltd. among 2,820 public biotech companies and publishes its news here as stories appear.

Which companies are similar to Psyrex CNS Bio-Tech?

Companies in our directory listed in the same country and business area as Psyrex CNS Bio-Tech: NRGENE TECHNOLOGIES LTD, Polyrizon, NEXTAGE Therapeutics, Evogene, BioLineRX, Compugen.

Investor discussion: Psyrex CNS Bio-Tech

Members talk about Psyrex CNS Bio-Tech (PSRX). Reader posts, not aibio.space reporting, and not investment advice.

Rules
  1. Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
  2. Say whether you hold the stock. Every post states long, short or no position.
  3. No paid or sponsored posts. Do not post for anyone who pays or rewards you.
  4. No buy or sell calls and no price targets.
  5. No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
  6. No personal details and no spam. No links at all for your first 7 days as a member.

Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.

Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open TASE:PSRX on TradingView.

Listing details

Psyrex CNS Bio-Tech Ltd. is a public biotech or pharmaceutical company listed on TASE under the ticker PSRX, recorded under Israel. The directory classifies it as Mixed biopharma / other operations. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Company
Psyrex CNS Bio-Tech Ltd.
Ticker
PSRX
Listing
TASE
Country or territory
Israel
Business scope
Mixed biopharma / other operations
ISIN
IL0011769085
Last quote in directory
2026-10-22
Directory source
Listing page

Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.

Published and maintained by aibio.space. Not investment advice. How we work.

Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction

aibio.space

Full desks

Every other company has a starter desk. Search above to open one.

Settings

Appearance
Text size
Motion

Stops the news strip and the share rollers.

Your choices are saved in this browser only.

Free membership

Read aibio.space in full, free

Subscribe with your email address to read every story, company desk and profile in full. It costs nothing. In return, you agree that we may email you, including offers. One click to unsubscribe.

No card, no password. With email, we send one message to confirm your address first. With Google or Facebook we receive only your email address. Not investment advice.